戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 er evaluation as a candidate vaccine against Japanese encephalitis.
2  novel live-attenuated viral vaccine against Japanese encephalitis.
3 thogens such as Brucella, leptospirosis, and Japanese encephalitis.
4 rrently, there is no effective treatment for Japanese encephalitis.
5 t viral-vectored vaccine for humans, against Japanese Encephalitis.
6  assess the efficacy of inteferon alfa-2a in Japanese encephalitis.
7 did not improve the outcome of patients with Japanese encephalitis.
8 s) in 112 Vietnamese children with suspected Japanese encephalitis, 87 of whom had serologically conf
9 own inteferon alfa has antiviral activity on Japanese encephalitis and other flaviviruses; therefore,
10 an be reliably prevented by vaccination (eg, Japanese encephalitis and rabies).
11     Vaccines are available for yellow fever, Japanese encephalitis and tick-borne encephalitis and se
12  genes of heterologous flaviviruses, such as Japanese encephalitis and West Nile viruses.
13                          Louis encephalitis, Japanese encephalitis, and dengue viruses.
14 uses - including dengue, Zika, yellow fever, Japanese encephalitis, and Powassan viruses - are mosqui
15              Flaviviruses such as West Nile, Japanese encephalitis, and tick-borne encephalitis (TBEV
16  of children admitted to hospital with acute Japanese encephalitis, and were confirmed serologically.
17 uracy of the IgG ELISA, and PRNTs with Zika, Japanese encephalitis, and West Nile viruses evaluated i
18  is closely related to yellow fever, dengue, Japanese encephalitis, and West Nile viruses, and vaccin
19  to the mosquito-borne yellow fever, dengue, Japanese encephalitis, and West Nile viruses, and vaccin
20 ccines have also been tested against dengue, Japanese encephalitis, and West Nile viruses.
21 enetic screening datasets, including dengue, Japanese encephalitis, and Zika viruses.
22  fever compared with non-vaccinees in the 75 Japanese encephalitis clusters in the cohort design (inc
23 viruses including dengue, chikungunya, Zika, Japanese encephalitis), endemic fungal infections (mucor
24 tis, such as herpes simplex encephalitis and Japanese encephalitis frequently relapse with autoimmune
25      Since it emerged in Japan in the 1870s, Japanese encephalitis has spread across Asia and has bec
26 ; interferon alpha was not effective against Japanese encephalitis in a double-blind placebo-controll
27                                              Japanese encephalitis is a major cause of death and disa
28                                              Japanese encephalitis is a mosquito-borne disease caused
29                                              Japanese encephalitis is an acute zoonotic, mosquito-bor
30            Although an effective vaccine for Japanese encephalitis is available, hundreds of millions
31                                              Japanese encephalitis is characterized by extensive infl
32                                              Japanese encephalitis (JE) causes at least 10 000 deaths
33                                              Japanese encephalitis (JE) is a mosquito-borne disease,
34                                              Japanese encephalitis (JE) is a vaccine-preventable acut
35                                              Japanese encephalitis (JE) is the leading cause of viral
36 merging Japanese encephalitis virus (JEV) or Japanese encephalitis (JE) serocomplex virus.
37 red the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on the efficacy o
38                          The live-attenuated Japanese encephalitis (JE) vaccine (JE-CV; IMOJEV) induc
39                    Live attenuated SA14-14-2 Japanese encephalitis (JE) vaccine has been safe and eff
40 assigned (1:1) to either Vi-TT or SA 14-14-2 Japanese encephalitis (JE) vaccine.
41                                              Japanese encephalitis (JE) virus (JEV) is an important c
42           A chimeric yellow fever (YF) virus/Japanese encephalitis (JE) virus vaccine (ChimeriVax-JE)
43     Similarly, the NS2B-NS3(178) protease of Japanese encephalitis (JE) virus, when substituted for t
44                                   ChimeriVax-Japanese encephalitis (JE), the first live- attenuated v
45 re, or concomitantly with, a vaccine against Japanese encephalitis (JE).
46 world population lives in areas with endemic Japanese encephalitis (JE).
47  Chikungunya (CHIKV), Yellow fever (YFV) and Japanese encephalitis (JEV) virus in different geographi
48 pes derived from dengue (DENV), Zika (ZIKV), Japanese encephalitis (JEV), West Nile (WNV), and yellow
49 lus influenzae type B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis s
50 sis, hepatitis B, tuberculosis, hepatitis A, Japanese encephalitis, meningitis A, and poliomyelitis)
51              Selectivity was validated using Japanese Encephalitis NS1, a homologous and potentially
52 ng polio, measles and rubella, yellow fever, Japanese encephalitis, rotavirus, and invasive bacterial
53 heir specificity in tests with yellow fever, Japanese encephalitis, St.
54 r, dengue, West Nile, St Louis encephalitis, Japanese encephalitis, tick-borne encephalitis, Kyasanur
55                                      Dengue, Japanese encephalitis, tick-borne encephalitis, yellow f
56 Vax-JE is a live, attenuated vaccine against Japanese encephalitis, using yellow fever (YF) 17D vacci
57 52]), but no significant association between Japanese encephalitis vaccination and typhoid fever was
58 ive antibody titres from a prior inactivated Japanese encephalitis vaccination enhanced yellow fever
59 and rubella elimination and the expansion of Japanese encephalitis vaccination in countries where it
60                          Using NCE analysis, Japanese encephalitis vaccination was associated with an
61 three) to receive two doses 1 month apart of Japanese Encephalitis vaccine (controls), 4CMenB, or one
62 bella vaccine and live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) are recommended for
63 e invited to receive a single dose of TCV or Japanese encephalitis vaccine between April 15, 2018, an
64 mparing vaccinees with non-vaccinees in both Japanese encephalitis vaccine clusters and TCV clusters,
65 ildren in the study area received the TCV or Japanese encephalitis vaccine during the baseline vaccin
66                    Children who received the Japanese encephalitis vaccine were invited to receive TC
67 at a regimen of two doses of live-attenuated Japanese encephalitis vaccine, administered 1 year apart
68 among recipients of TCV versus recipients of Japanese encephalitis vaccine-with estimates from cohort
69      JENVAC is now licensed as a single-dose Japanese encephalitis vaccine.
70 omly assigned (1:1) to receive either TCV or Japanese encephalitis vaccine.
71                             Yellow fever and Japanese encephalitis vaccinees were less reactive in th
72                                      Current Japanese encephalitis vaccines are derived from strains
73 vaccines such as typhoid conjugate (TCV) and Japanese encephalitis vaccines are risk based and only u
74 cation in domesticated animals, as seen with Japanese encephalitis, Venezuelan equine encephalitis, a
75 rresponding genes of an attenuated strain of Japanese encephalitis virus (JE), SA14-14-2.
76 ll eight live attenuated vaccines, including Japanese encephalitis virus (JEV) (SA-14-14-2), varicell
77                                     Although Japanese encephalitis virus (JEV) accounts for around 15
78  virus (TBEV), yellow fever virus (YFV), and Japanese encephalitis virus (JEV) and by comparing the r
79 y for the presumptive serodiagnosis of acute Japanese encephalitis virus (JEV) and West Nile virus (W
80        First, RC-101 robustly inhibited both Japanese encephalitis virus (JEV) and Zika virus (ZIKV)
81                            Four genotypes of Japanese encephalitis virus (JEV) are presently recogniz
82  dengue viruses (DENV), West Nile virus, and Japanese encephalitis virus (JEV) are widely used as ser
83                                        Using Japanese encephalitis virus (JEV) as a model, we perform
84                   A yellow fever virus (YFV)/Japanese encephalitis virus (JEV) chimera in which the s
85          In recent years, genotype I (GI) of Japanese encephalitis virus (JEV) has displaced genotype
86     However, the precise role of IRF8 during Japanese encephalitis virus (JEV) infection in the brain
87                                              Japanese encephalitis virus (JEV) invades the CNS, resul
88 terventions against neurotropic flaviviruses.Japanese encephalitis virus (JEV) is a Flavivirus respon
89                                              Japanese encephalitis virus (JEV) is a leading cause of
90                                              Japanese encephalitis virus (JEV) is a major threat to h
91                                              Japanese encephalitis virus (JEV) is a mosquito-borne zo
92                                              Japanese encephalitis virus (JEV) is a zoonotic, mosquit
93                                              Japanese encephalitis virus (JEV) is the leading global
94 ed vaccine candidates against newly emerging Japanese encephalitis virus (JEV) or Japanese encephalit
95 crophages in the brain, play a vital role in Japanese encephalitis virus (JEV) pathogenesis.
96                   Plasmid vectors containing Japanese encephalitis virus (JEV) premembrane (prM) and
97 e safety and efficacy of the live-attenuated Japanese encephalitis virus (JEV) SA14-14-2 vaccine are
98 tis virus (TBEV), West Nile virus (WNV), and Japanese encephalitis virus (JEV) that could complement
99 is is a mosquito-borne disease caused by the Japanese encephalitis virus (JEV) that is prevalent in A
100 , immunogenicity, and protective efficacy of Japanese encephalitis virus (JEV) virus-like particles (
101                                              Japanese encephalitis virus (JEV), a mosquito-borne flav
102                                              Japanese encephalitis virus (JEV), a mosquito-borne flav
103                                              Japanese encephalitis virus (JEV), although confined to
104 viviruses, such as West Nile virus (WNV) and Japanese encephalitis virus (JEV), POWV disease presenta
105 containing EIIIs from Koutango virus (KOUV), Japanese encephalitis virus (JEV), St. Louis encephaliti
106 s have routine vaccination campaigns against Japanese encephalitis virus (JEV), the effect of JEV imm
107 cation of three flaviviruses, DENV, WNV, and Japanese encephalitis virus (JEV), using a high-content
108                                 We diagnosed Japanese encephalitis virus (JEV), using antibody detect
109 ENV-1 to DENV-4), West Nile virus (WNV), and Japanese encephalitis virus (JEV), were constructed.
110 c amplification of yellow fever virus (YFV), Japanese encephalitis virus (JEV), West Nile virus (WNV)
111                                              Japanese encephalitis virus (JEV)-specific Fab antibodie
112  dengue virus (DENV), Zika virus (ZIKV), and Japanese encephalitis virus (JEV).
113  dengue virus (DENV), Zika virus (ZIKV), and Japanese encephalitis virus (JEV).
114 e zoonotic, mosquito-borne disease caused by Japanese encephalitis virus (JEV).
115 le virus (WNV), hepatitis C virus (HCV), and Japanese encephalitis virus (JEV).
116 dengue virus (DENV; nine isolates analyzed), Japanese encephalitis virus (JEV; one isolate analyzed)
117  were vaccinated with yellow fever, chimeric Japanese encephalitis virus (YF/JE), or chimeric West Ni
118 e, yellow fever, tick-borne encephalitis and Japanese encephalitis virus among many others.
119     Multiple known zoonotic viruses, such as Japanese encephalitis virus and mammalian orthoreovirus(
120 we found evidence of endemic transmission of Japanese encephalitis virus and recent outbreaks of deng
121 cryo-electron microscopy structure of mature Japanese encephalitis virus at near-atomic resolution, w
122 is are either preventable or treatable, with Japanese encephalitis virus being the most common cause.
123 es, assessed plasmid VRC5288 (Zika virus and Japanese encephalitis virus chimera), and the VRC 320, d
124                                In Australia, Japanese encephalitis virus circulated in tropical north
125 its divergence from the other members of the Japanese encephalitis virus complex, presumably in Afric
126                   The global epidemiology of Japanese encephalitis virus has been further clarified.
127 easles, pertussis, meningococcal disease and Japanese encephalitis virus have been linked to lack of
128  the neurovirulence and neuroinvasiveness of Japanese encephalitis virus in mice.
129 how reduced production of dengue virus-2 and Japanese encephalitis virus in these cells.
130 in critical for dengue hemorrhagic fever and Japanese encephalitis virus infection, inhibits NLRP3 in
131                                    Globally, Japanese encephalitis virus is the most important emergi
132 fferent flaviviruses may cause encephalitis, Japanese encephalitis virus is the most significant, bei
133  DENV NS1 with the corresponding region from Japanese encephalitis virus NS1 to create chimeric DJ NS
134 ve epitopes with the corresponding region of Japanese encephalitis virus NS1 to generate a chimeric D
135      The presence of dengue virus (DENV) and Japanese encephalitis virus NS1s in the blood of infecte
136                         Recent work suggests Japanese encephalitis virus originated in the Indonesia-
137 eronegative individuals were seropositive to Japanese encephalitis virus prior to their infection).
138 tick-borne encephalitis virus serogroup) and Japanese encephalitis virus use the nonstructural protei
139  (63.6%) were seropositive for Zika virus or Japanese encephalitis virus with FRNT.
140 patients: 216 (33%) of 664 cases were due to Japanese encephalitis virus, 27 (4%) were due to dengue
141 s of the flavivirus family: West Nile virus, Japanese encephalitis virus, and dengue virus 2.
142 yzed by related helicases from Dengue virus, Japanese encephalitis virus, and humans.
143  simplex virus, varicella zoster virus, HIV, Japanese encephalitis virus, and SARS-CoV-2, are linked
144 er (WNF), chikungunya, dengue, yellow fever, Japanese encephalitis virus, GBS, and control datasets.
145 lly include viral (for example, HIV, rabies, Japanese encephalitis virus, herpes simplex virus, varic
146                    Louis encephalitis virus, Japanese encephalitis virus, Kunjin virus, Murray Valley
147 erminants of neurovirulence and stability in Japanese encephalitis virus, opening up new avenues for
148 ovirus, metapneumovirus, yellow fever virus, Japanese encephalitis virus, parainfluenza virus and Sen
149              In addition to the plasmids for Japanese encephalitis virus, West Nile virus (WNV), St.
150 ated also with epidemics, required RelA, and Japanese encephalitis virus, which produced relatively m
151 nodeficiency virus 1, hepatitis C virus, and Japanese encephalitis virus.
152 milarities to the NS5 protein of the related Japanese encephalitis virus.
153  human pathogens, including dengue virus and Japanese encephalitis virus.
154 fever virus, dengue virus types 2 and 4, and Japanese encephalitis virus.
155 virus genus (including dengue, West Nile and Japanese encephalitis viruses) is regulated by a wide va
156  flaviviruses include dengue, West Nile, and Japanese encephalitis viruses, and the nonpathogenic fla
157 iruses including yellow fever, West Nile and Japanese encephalitis viruses.
158 an epidemic-causing dengue, yellow fever and Japanese encephalitis viruses.
159 laviviruses such as tick-borne encephalitis, Japanese encephalitis, yellow fever and dengue viruses,
160      Specifically, sfRNAs from Dengue, Zika, Japanese Encephalitis, Yellow Fever, Murray Valley Encep
161 veloped for generating chimeric yellow fever/Japanese encephalitis (YF/JE) viruses from cDNA template
162 etween heterologous challenges of West Nile, Japanese encephalitis, Zika, and dengue viruses did not

 
Page Top